Patrizio Armeni

Bocconi University

H指数:19

被引数:1,317

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Promoting healthy aging in a digital world: leveraging technology for enhanced elderly care and wellbeing

更正：在数字世界中促进健康老龄化：利用技术提升老年护理和福祉

Frontiers in Aging

IF4.3

2026-10-010

OAAI

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy

固定疗程疗法对意大利慢性淋巴细胞白血病患者管理中的组织影响

BMC Health Services Research

IF3

2026-05-040

OAAI

Implementing the EU HTA regulation and joint clinical assessment: a multi-stakeholder perspective from Italy

实施欧盟HTA法规和联合临床评估：来自意大利的多利益相关方视角

International Journal of Technology Assessment in Health Care

IF3.1

2026-04-170

OAAI

Promoting healthy aging in a digital world: leveraging technology for enhanced elderly care and wellbeing

在数字世界中促进健康老龄化: 利用技术增强老年人护理和福祉

Frontiers in Aging

IF4.3

2026-02-040

The relationship between trust and compliance in the Italian NHS: results of the People's Voice Survey

信任与合规之间的关系：意大利国家卫生服务系统“人民之声”调查结果

Health Policy

IF3.4

2025-12-110

OAAI

The economic burden of anesthetic-related adverse events: a systematic review and empirical analysis

麻醉相关不良事件的经济负担：一项系统综述和实证分析

BMC ANESTHESIOLOGY

IF2.6

2025-11-060

OAAI

The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States

卫生系统在塑造疫苗决策中的作用：来自意大利、墨西哥、英国和美国的见解

VACCINE

IF3.5

2025-04-011

OAAI

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case

JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE

IF2.5

2024-03-1113

OAAI

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy

ADVANCES IN THERAPY

IF4

2024-02-082

OAAI

Health system quality and COVID-19 vaccination: a cross- sectional analysis in 14 countries

LANCET GLOBAL HEALTH

IF18

2024-01-015

OAAI

Collecting Physicians' Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopaedists Using 2 Different Stated Preference Methods

MEDICAL DECISION MAKING

IF2.3

2023-10-142

OAAI

Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe

health policy

IF3.7

2023-09-016

OAAI

Comment on Emerging Approaches to DNA Data Storage: Challenges and Prospects

ACS NANO

IF16

2022-12-271

PRE

Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma

CLINICAL THERAPEUTICS

IF3.6

2022-11-013

PRE

Digital Twins in Healthcare: Is It the Beginning of a New Era of Evidence-Based Medicine? A Critical Review

JOURNAL OF PERSONALIZED MEDICINE

IF3

2022-07-3067

Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

EXPERT OPINION ON BIOLOGICAL THERAPY

IF4

2022-04-2611

PRE

Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies

HEALTH POLICY

IF3.4

2021-05-0121

OAAI

Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service

CLINICAL THERAPEUTICS

IF3.6

2020-07-016

PREAI

Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service

CLINICAL THERAPEUTICS

IF3.6

2020-05-0115

PREAI

Implementation of Value-based Pricing for Medicines

CLINICAL THERAPEUTICS

IF3.6

2020-01-0150

OAAI

Patrizio Armeni

个人简介

教育背景

工作经历

荣誉奖项

研究方向